---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-073909"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:34:13.432654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026

## Summary
- Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.
- Net loss $67.8M ($0.39/share) vs $43.8M ($0.26) YoY; R&D spend $51.1M (up 77%) driven by SOL trial costs.
- Cash $391.1M; raised ~$97M via ATM in June; runway into 2028, well beyond SOL-1 and SOL-R data.
- SOL-1 Phase 3 wet AMD top-line data on track for Q1 2026; SOL-R data expected 1H 2027 with streamlined rescue criteria.
- Received FDA feedback on NPDR/DME program; Investor Day Sept 30 in NYC to detail strategy and commercial outlook.

## SEC filing metadata
- accession: 0001104659-25-073909
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/0001104659-25-073909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-073909
- JSON: https://secwatch.observer/filing/0001104659-25-073909.json
- Plain text: https://secwatch.observer/filing/0001104659-25-073909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.